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The influence of aneurysm size on perioperative
cardiac outcome in elective open infrarenal aortic
aneurysm repair
Olaf Schouten, MD,a Niels F. M. Kok, MD,a Marco T. C. Hoedt, MD,b Jorinde H. H. van Laanen, MD,c
andDon Poldermans, MD,d Rotterdam, Dordrecht, and Delft, The Netherlands
Background: Abdominal aortic aneurysm (AAA) size and growth has been found to be associated with local generation of
inflammation markers such as interleukin-6. Inflammation also seems to be important in perioperative adverse cardiac
events. We hypothesized that patients with a large AAA are at increased risk for cardiac events.
Methods: Consecutive patients who underwent a computed tomography angiography scan before open elective infrarenal
AAA repair between March 2000 and December 2005 at three hospitals were analyzed. All patients were screened for the
clinical risk factors of age, gender, angina pectoris, myocardial infarction, heart failure, diabetes, stroke, renal failure, and
chronic obstructive pulmonary disease, as well as for cardioprotective medication. Postoperative data on troponin release,
creatine kinase/creatine kinase isoenzyme MB, and electrocardiogram were routinely collected on days 1, 3, 7, and 30.
The main outcome measure was the combined end point of 30-day cardiovascular death and nonfatal myocardial
infarction. Multivariate Cox regression analysis was used to evaluate the influence of AAA size on postoperative cardiac
outcome.
Results: The study included 500 patients. Their mean age was 69.8  9.5 years, and 431 (86%) were men. Thirty-one
patients (6.2%) had perioperative cardiovascular complications, consisting of 15 (3.0%) cardiovascular deaths and 16
(3.2%) nonfatal myocardial infarctions. After correction for other risk factors, including age, Revised Cardiac Risk Index,
medication use, duration of surgery, and intraoperative blood loss, AAA size was independently associated with
perioperative nonfatal myocardial infarction and cardiovascular death (3.2% increase in risk for each millimeter added,
95% confidence interval 1.1% to 6.2%, P  .007).
Conclusion: A larger AAA size is independently associated with an increased incidence of perioperative cardiovascular
complications after elective infrarenal AAA repair. ( J Vasc Surg 2006;44:435-41.)Abdominal aortic aneurysm (AAA) occurs frequently in
the elderly population, with a 5% to 7% prevalence in men
aged 65 to 74 years that increases to 10% in men 74
years old.1-3 The overall mortality from ruptured AAA
remains high, at up to 75%, and preventive elective repair of
large AAAs appears to be the best option.4 Perioperative
cardiac complications of elective AAA repair remain a sig-
nificant problem, however, despite recent perioperative
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The pathophysiology of these perioperative adverse
cardiac events is not entirely clear. Coronary plaque insta-
bility caused by inflammation that leads to thrombosis and
myocardial infarction is a major cause of perioperative
cardiac events, similar to myocardial infarctions occurring
in the nonoperative setting.7 At least two studies evaluating
the pathophysiology of perioperative myocardial infarction
using noninvasive tests, coronary angiography, and autopsy
results showed that coronary plaque rupture and thrombus
formation occurred in about 50% of all fatal cases, and a
sustained mismatch of oxygen supply and demand was
responsible for the remaining half.8,9
It has been shown that AAAs might be an important
source of circulating inflammatory markers such as inter-
leukin (IL)-6, serum amyloid A, C-reactive protein (CRP),
and high-sensitivity (hs) CRP. These inflammatory markers
are also positively related to the abdominal aortic size.10-13
As was recently shown, the concentration of inflammatory
markers such as IL-6 and hsCRP is predictive for adverse
cardiac events in patients with peripheral arterial disease.14
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long-term cardiovascular mortality.
Because AAA size and growth seems to be related to
the concentration of circulating proinflammatory markers
and to long-term cardiac outcome, we hypothesized that
patients with a large AAA might be more prone to adverse
perioperative cardiac events after AAA repair than patients
with small AAAs. We conducted the present study to eval-
uate this hypothesis.
METHODS
Patient population. The study population was com-
posed of all consecutive patients who underwent a com-
puted tomography angiography (CTA) scan before elective
open infrarenal AAA repair between March 2000 and De-
cember 2005 at one of three hospitals (Erasmus University
Medical Center in Rotterdam, Albert Schweitzer Hospital
in Dordrecht, and Reinier de Graaf Hospital in Delft, the
Netherlands). Surgical medical charts were screened to
retrospectively identify patients.
A CTA scan of the AAA before surgical repair to measure
the maximum diameter of the AAA was required to be in-
cluded in this analysis. All CTA scans were scored, including
maximum diameter, by the attending radiologist. In a weekly
meeting of radiologists and vascular surgeons, the measure-
ments of the AAAs were reviewed and adjusted, if neces-
sary, after consensus was reached.
To obtain a more homogenous study population, pa-
tients with an inflammatory or mycotic aneurysm were
excluded from analysis. All operation reports were screened
to make sure only patients requiring infrarenal aortic cross-
clamping were included in the analysis. The study was
approved by the Medical Ethics Committee of the Erasmus
Medical Center.
Perioperative cardiac risk assessment. All patients
were screened for cardiac risk factors, including age, hyper-
tension (ie, medical therapy to control hypertension), a
history or presence of angina pectoris, previous myocardial
infarction, heart failure, stroke, renal failure (ie, a serum
creatinine of 2.0 mg/dL), and diabetes mellitus. Also
noted were smoking status (never, current, or former) and
the presence of chronic obstructive pulmonary disease
(COPD). A patient was classified as having COPD at the
preoperative screening visit according to symptoms and
pulmonary function test (ie, forced expiratory volume of 1
second of 70% of maximal age and gender predictive
value). Heart failure was scored according to the notes
of the preoperative screening visits as well. Duration of
surgery and intraoperative blood loss were noted in all
patients.
All prescription and over-the-counter medications
were noted on the day of admission and were classified as
follows: statins, -blockers, platelet aggregation inhibitors,
angiotensin-converting enzyme inhibitors, calcium-channel
blockers, diuretics, and nitrates. Patients unable to take oral
medication perioperatively were switched to an intravenous
formula. If no intravenous formula was available (ie, statinsand angiotensin-converting enzyme inhibitors), oral med-
ication was restarted as soon as possible after surgery.
Outcome. The main outcome measure was the com-
bined end point of 30-day cardiovascular death and nonfa-
tal myocardial infarction. Secondary 30-day all-cause mor-
tality was analyzed. Cardiovascular death was defined as any
death with a cardiovascular cause, including those deaths
after a cardiac procedure, cardiac arrest, myocardial infarc-
tion, pulmonary embolus, stroke, or sudden deaths not
ascribed to other causes. Myocardial infarction was defined
as the presence of two of the following three criteria: (1)
characteristic ischemic symptoms lasting 20 minutes, (2)
electrocardiographic changes including acute ST elevation
followed by appearance of Q waves or loss of R waves, new
left bundle branch block, new persistent T wave inversion
for at least 24 hours, or new ST segment depression which
persists24 hours, and (3) a positive troponin T (ie,0.10
ng/mL) or peak creatinine phosphokinase-MB 8% of an
elevated total creatinine phosphokinase with characteristic
rise and fall.16 To assess cardiac complications during the
postoperative period, blood and plasma samples for cardiac
troponin T, creatinine phosphokinase levels, creatinine
phosphokinase-MB levels, and electrocardiography were
collected on 1, 3, 7 (or at the day of discharge), and 30 days
after surgery.
Statistical analysis. Continuous variables were de-
scribed as mean value (range), and categoric variables as
percent frequencies. Linear regression analysis was used to
explore the relation between aneurysm size and duration of
surgery and blood loss. Kaplan-Meier survival curves were
constructed to assess perioperative cardiovascular event-
free and overall survival. The association of AAA size,
cardiovascular risk factors, and medication use with periop-
erative cardiovascular complications and all-cause death
was assessed via multivariate Cox regression analysis. All
covariables associated with perioperative cardiac complica-
tions or all-cause mortality (P  .20 in univariate analysis)
were included in the multivariate model.
The number of outcome events in the study was lim-
ited. Therefore, to avoid overfitting and to enable assess-
ment of the relation between clinical risk factors and the
perioperative composite end point, we used the Revised
Cardiac Risk Index.17 The Revised Cardiac Risk Index
identifies high-risk surgery, ischemic heart disease, conges-
tive heart failure, cerebrovascular disease, insulin-dependent
diabetes mellitus, and renal failure as the six predictors of
major cardiac complications. Based on the presence of 0, 1,
2, or 3 of these predictors, the rate of major cardiac
complications was estimated to be 0.4%, 0.9%, 7%, and
11%, respectively, in the original study by Lee et al,18
resulting in an excellent area under the curve (AUC) of
0.81. Receiver operating characteristic curve analysis was
performed to calculate AUC values. The performance of
riskmodels can be determined by the AUC, which indicates
how well a model rank orders patients with respect to their
outcomes, where 0.5 indicates no predictive value and 1.0
indicates perfect performance.16 The limit of statistical
significance was set at P  .05 (two sided). All analysis was
as rang
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Inc, Chicago, Ill) for Windows (Microsoft, Redmond,
Wash).
RESULTS
Patient characteristics. The study included 500 pa-
tients with an infrarenal AAA. Their mean age was 70  9.5
years, and 86%weremen. The overall medianmaximumAAA
diameter was 56 mm (range, 42 to 110 mm). According to
the Revised Cardiac Risk index classification, almost half of
the patients (41%) had one risk factor (ie, high-risk type of
surgery), whereas 33% and 26% had two and three or more
risk factors. Baseline clinical characteristics and medication
use are presented in Table I. The median duration of
surgery was 216 minutes, and median blood loss during
surgery was 2100 mL. Neither duration of surgery (P 
.78) nor blood loss during surgery (P .13) was related to
AAA size.
Perioperative cardiovascular outcome. Perioperative
cardiac events occurred in 31 patients (6.2%), including
cardiovascular death in 15 and nonfatal myocardial infarc-
tion in 16. In univariate analysis age, AAA diameter and
Revised Cardiac Risk Index were associated with worse
outcome, and -blocker therapy and statin therapy were
associated with a reduced incidence of perioperative ad-
verse cardiac events (Table II). In multivariate analysis,
AAA size was associated with an increased incidence of
perioperative cardiac events (3.2% increase in risk for each
Table I. Baseline characteristics, surgery, and medication
or without perioperative events
All patients (n  500)
Men 431 (86)
Age (mean SD) 70  9.5
Median AAA size (mm, range) 56 (42-110)
Median duration of surgery (min, range) 216 (120-535)
Median blood loss (mL, range) 2100 (400-18000)
Previous angina pectoris 110 (22)
Previous MI 163 (33)
Previous heart failure 26 (5)
CVA or TIA 77 (15)
Diabetes mellitus 48 (10)
Renal failure 28 (6)
Systemic hypertension 207 (42)
COPD 127 (25)
Revised Cardiac Risk Index
1 risk factor 203 (41)
2 risk factors 165 (33)
3 risk factors 132 (26)
Platelet aggregation inhibitors 178 (36)
ACE inhibitors 152 (31)
Diuretics 84 (17)
Nitrates 66 (13)
-blockers 364 (73)
Statins 202 (40)
Calcium antagonists 157 (31)
MI,Myocardial infarction; CVA, cerebrovascular accident; TIA, transient is
converting enzyme.
*Data are numbers and percentages in parenthesis, except where indicatedmillimeter added; 95% confidence interval [CI], 1.1% to6.2%, P  .007). Furthermore, age and a higher score of
the Revised Cardiac Risk Index were associated with an
increased risk of perioperative cardiac events (Table II).
ROC analysis showed an AUC of 0.60 for the Revised
Cardiac Risk Index alone, but this AUC improved to 0.69
if AAA size was added to the model (P  .001). If age was
also added to the model, the AUC further improved to
0.75 (P .003). -Blocker therapy and statin therapy were
both associated with a reduced incidence of perioperative
cardiac events in multivariate analysis (hazard ratio, 0.31;
95% CI 0.15 to 0.63; and hazard ratio, 0.40; 95% CI 0.16
to 0.95, respectively).
Perioperative all-cause mortality. Twenty-nine pa-
tients (5.8%) died during the first 30 days after AAA repair.
Fifteen deaths (52%) were caused by cardiovascular com-
plications, 4 (14%) by respiratory complications, 6 (21%) by
multiorgan failure, and 4 (14%) by other complications.
The results of univariate analysis are shown in Table III.
The size of AAA was not significantly associated with
perioperative all-cause death (P  .08) in univariate analy-
sis. In multivariate analysis (Table III), AAA size was also
not associated with an increase or reduction in periopera-
tive all-cause mortality (adjusted odds ratio for every milli-
meter increase in size, 1.02; 95% CI, 0.98 to 1.05; P 
.35). Two or more clinical risk factors and increased age
were associated with an increased incidence of 30-day
mortality in multivariate analysis. Statin therapy and
-blocker therapy were associated with an approximate
uring hospitalization of all patients and in patients with
tients without events (n  469)* Patients with events (n  31)*
404 (86) 27 (87)
70.3 (60-89) 73.5 (64-89)
56 (42-110) 66 (47-95)
216 (120-500) 210 (140-535)
2100 (400-18000) 3100 (2000-6500)
101 (22) 9 (29)
150 (32) 13 (42)
24 (5) 2 (7)
72 (15) 5 (16)
45 (10) 3 (10)
24 (5) 4 (13)
197 (43) 10 (33)
115 (25) 12 (39)
195 (42) 8 (26)
154 (33) 11 (36)
120 (26) 12 (39)
170 (36) 8 (26)
144 (31) 8 (26)
80 (17) 4 (13)
60 (13) 6 (19)
349 (74) 15 (48)
196 (42) 6 (19)
147 (32) 10 (32)
c attack; COPD, chronic obstructive pulmonary disease; ACE, angiotensin-
es, and means  SD.use d
* Pa
chemifourfold relative risk reduction (Table III).
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This study showed an association between AAA size
and perioperative cardiovascular complications after elec-
tive infrarenal AAA repair irrespective of other known fac-
tors influencing perioperative cardiovascular outcome. This
study also showed a beneficial effect of both statin therapy
and -blocker therapy in patients undergoing open AAA
Table II. Perioperative cardiac death and nonfatal myocar
Uni
OR
Men 1.09
Age (per year increase) 1.09
AAA diameter (per mm increase) 1.04
Intraoperative blood loss (per 500-mL increase) 1.06
Duration of surgery (per 10-min increase) 1.02
Systemic hypertension 0.68
COPD 1.91
Revised Cardiac Risk Index
1 risk factor 1
2 risk factors 1.73
3 risk factors 2.35
Medication use
Platelet aggregation inhibitors 0.62
ACE inhibitors 0.79
Diuretics 0.73
Nitrates 1.58
-blockers 0.34
Statins 0.35
Calcium antagonists 1.04
AAA, Abdominal aortic aneurysm; COPD, chronic obstructive pulmonary
Odds ratio (OR), 95% confidence intervals (CI) and P values in univariate
regression analysis.
Table III. Perioperative all-cause mortality
Univ
OR
Men 1.39
Age (per year increase) 1.10
AAA diameter (per mm increase) 1.02
Intraoperative blood loss (per 500-mL increase) 1.14
Duration of surgery (per 10-min increase) 1.02
Systemic hypertension 1.51
COPD 1.83
Revised Cardiac Risk Index
1 risk factor
2 risk factors 2.79
3 risk factors 4.16 1
Medication use
Platelet aggregation inhibitors 0.82
ACE-inhibitors 0.73
Diuretics 1.96
Nitrates 1.06
-blockers 0.29
Statins 0.30
Calcium antagonists 2.08
AAA, Abdominal aortic aneurysm; COPD, chronic obstructive pulmonary
Odds ratio (OR), 95% confidence intervals (CI), and P values in univariate
regression analysis.repair.The overall 30-day mortality rate of 5.8% is in line with
other studies on open infrarenal AAA repair.17 Our study
confirmed the observation from previous reports that ap-
proximately half of all perioperative deaths after AAA repair
are attributable to cardiovascular complications. The 6.2%
perioperative overall cardiac event rate of our study empha-
sizes the high cardiac risk for patients undergoing vascular
infarction
te analysis Multivariate analysis
CI P Adjusted OR 95% CI P
-3.12 .87
-1.14 .001 1.07 1.02-1.12 .01
-1.06 .001 1.03 1.01-1.06 .007
-1.22 .41
-1.07 .43
-1.46 .68
-3.93 .08 1.81 0.85-3.89 .13
-4.30 .24 2.30 0.92-5.76 .07
-5.75 .06 3.55 1.40-8.99 .008
-1.40 .25
-1.78 .58
-2.10 .56
-3.86 .31
-0.69 .003 0.31 0.15-0.63 .01
-0.85 .02 0.40 0.16-0.95 .04
-2.20 .92
e; ACE, angiotensin-converting enzyme.
is by means of the log-rank test, and multivariate analysis by means of Cox
e analysis Multivariate analysis
CI P Adjusted OR 95% CI P
-4.58 .59
-1.15 .001 1.09 1.03-1.15 .005
-1.05 .08 1.02 0.98-1.05 .35
-1.28 .04 1.07 1.01-1.17 .04
-1.08 .39
-3.21 .28
-3.87 .12 1.50 0.63-3.58 .36
-8.02 .06 3.28 1.11-9.72 .03
1.66 .007 4.88 1.62-14.67 .005
-1.79 .61
-1.70 .46
-4.43 .11 2.10 0.79-5.61 .14
-3.04 .91
-0.61 .001 0.21 0.10-0.45 .001
-0.79 .02 0.26 0.11-0.76 .01
-4.32 .05 2.10 0.89-4.82 .09
e; ACE, angiotensin-converting enzyme.
sis by means of the log-rank test and multivariate analysis by means of Coxdial
varia
95%
0.38
1.04
1.02
0.92
0.97
0.32
0.93
0.70
0.96
0.28
0.36
0.26
0.65
0.17
0.14
0.49
diseas
analysariat
95%
0.42
1.04
0.99
1.01
0.97
0.71
0.86
0.97
.48-1
0.37
0.31
0.87
0.37
0.14
0.12
1.01
diseas
analysurgery.
yoca
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lence of asymptomatic coronary artery disease in AAA
patients. As was shown by Hertzer et al19 in a study
involving 1000 vascular surgical patients undergoing coro-
nary angiography, 60% of patients with an AAA have
some form of coronary artery disease. These lesions may
cause a myocardial supply and demand imbalance owing
to prolonged tachycardia and increased myocardial con-
tractility,20 and thus are thought to be responsible for
approximately half of all postoperative myocardial infarc-
tions. This hypothesis has been confirmed in at least two
studies using noninvasive tests, coronary angiography, and
autopsy results.8,9
The other 50% of myocardial infarctions might be
caused by sudden rupture of so-called vulnerable coronary
plaques. Surgery imposes extra myocardial workload, re-
sulting in mechanical stress, stress-induced inflammation,
and possibly spasms. This can cause vulnerable plaques to
become unstable, leading to the cascade of plaque rupture,
thrombus formation, myocardial ischemia, myocardial in-
farction, and eventually death.
Naghavi et al,7,21 in their extensive review on vulnera-
ble plaques, reported that inflammation is one of the major
criteria in the definition of vulnerable plaques. It is gener-
ally well accepted that inflammation is of imminent impor-
tance in the whole process. Therefore, most research has
been focused on inflammation of coronary plaques as the
Infiltration of coronary
Rupture of coronary plaque
Myocardial infarction
Fig. From abdominal aortic aneurysm (AAA) to multimate trigger for vulnerable plaque rupture. This interestin inflammatory components has been justified in several
population-based studies in which a positive relationship
between inflammation markers and the occurrence of car-
diovascular events was found.22
In recent studies, the presence of an abdominal aortic
aneurysm was positively related to circulating inflammatory
markers. These inflammatory markers include IL-1-,
IL-6, tumor necrosis factor-, interferon-, CRP, and
hsCRP.10-13,23 Importantly, both Jones et al10 and Rohde
et al12 found a positive correlation between circulating IL-6
levels and AAA size. Vainas et al11 found a similar correla-
tion between hsCRP and AAA size. Also of importance is
that they found CRP messenger RNA in AAA tissue.11
From these observations, it might be hypothesized that
aneurysmal tissue produces inflammatory markers: Patients
with an AAA have a higher level of circulating inflammatory
markers, and patients with a large AAA have a higher level
of circulating inflammatory markers than patients with
small AAAs. A different hypothesis might also be true,
however: Patients with an elevated inflammatory status may
be more prone to AAA development and growth than
patients with a normal inflammatory status. Subsequently,
patients with an elevated inflammatory status have a faster
growing, larger AAA. Which hypothesis is true remains
unknown, and further research in this area is required.
Large, prospective population-based studies have
shown that circulating levels of hsCRP and IL-6 are related
Production of inflammatory 
markers in AAA wall
e
rdial infarction in patients undergoing AAA repair.plaquto long-term cardiac outcome. In a study by Ridker et al,24
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a 6-year follow-up in 404 patients. Also supported by
several clinical studies is the association of elevated hsCRP
levels with long-term adverse cardiac events.
Because patients with large AAAs seem to have an
elevated inflammatory status compared with patients with
small AAAs, it might be hypothesized that patients with a
large AAA are more prone to vulnerable plaque rupture
than patients with a small AAA (Fig). This hypothesis was
confirmed by Brady et al in a group of 2305 patients; AAA
size was associated with a 34% increased risk for cardiovas-
cular long-term mortality for every 0.8 cm added to AAA
size.15
The outcome of the UK Small Aneurysm Trial did not
show a relation between AAA size and perioperative all-
cause 30-day mortality.25 Our study confirmed this obser-
vation: No association between AAA size and perioperative
all-cause mortality was found. Unfortunately, theUK Small
Aneurysm Trial did not reported on cardiac death. It would
be interesting to evaluate recent prospective trials on infra-
renal abdominal aneurysm repair such as the UK Small
Aneurysm Trial, the Dutch Randomised Endovascular An-
eurysm Management trial,26 and Endovascular Aneurysm
Repair-1 trial27 for the relationship between AAA size and
postoperative cardiac outcome.
This study has several limitations owing to its retrospec-
tive nature. Autopsy was performed in only a few patients
who died, and thus, misclassification of cause of death
might have occurred. Also, there was no prespecified pro-
tocol for the measurement of the maximum abdominal
aortic diameter and the measurement of this diameter was
done on the basis of institutional common practice. Fur-
thermore no information on the inflammatory state of our
study population (eg, IL-6 and high-sensitivity CRP levels)
was available.
CONCLUSION
This study shows a clear association between AAA size
and postoperative cardiac outcome, irrespective of other
known risk factors. Future studies on the influence of AAA
size on perioperative outcome should, if possible, also
include the patients’ inflammatory status.
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